Cargando…
Current perspectives on bone metastases in castrate-resistant prostate cancer
Prostate cancer is the most frequent noncutaneous cancer occurring in men. On average, men with localized prostate cancer have a high 10-year survival rate, and many can be cured. However, men with metastatic castrate-resistant prostate cancer have incurable disease with poor survival despite intens...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801387/ https://www.ncbi.nlm.nih.gov/pubmed/29380085 http://dx.doi.org/10.1007/s10555-017-9719-4 |
_version_ | 1783298338827796480 |
---|---|
author | Logothetis, Christopher Morris, Michael J. Den, Robert Coleman, Robert E. |
author_facet | Logothetis, Christopher Morris, Michael J. Den, Robert Coleman, Robert E. |
author_sort | Logothetis, Christopher |
collection | PubMed |
description | Prostate cancer is the most frequent noncutaneous cancer occurring in men. On average, men with localized prostate cancer have a high 10-year survival rate, and many can be cured. However, men with metastatic castrate-resistant prostate cancer have incurable disease with poor survival despite intensive therapy. This unmet need has led to recent advances in therapy aimed at treating bone metastases resulting from prostate cancer. The bone microenvironment lends itself to metastases in castrate-resistant prostate cancer, as a result of complex interactions between the microenvironment and tumor cells. The development of (223)radium dichloride (Ra-223) to treat symptomatic bone metastases has improved survival in men with metastatic castrate-resistant prostate cancer. Moreover, Ra-223 may have effects on the tumor microenvironment that enhance its activity. Ra-223 treatment has been shown to prolong survival, and its effects on the immune system are under investigation. Because prostate cancer affects a sizable portion of the adult male population, understanding how it metastasizes to bone is an important step in advancing therapy. Clinical trials that are underway should yield new information on whether Ra-223 synergizes effectively with immunotherapy agents and whether Ra-223 has enhancing effects on the immune system in patients with prostate cancer. |
format | Online Article Text |
id | pubmed-5801387 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-58013872018-02-14 Current perspectives on bone metastases in castrate-resistant prostate cancer Logothetis, Christopher Morris, Michael J. Den, Robert Coleman, Robert E. Cancer Metastasis Rev Clinical Prostate cancer is the most frequent noncutaneous cancer occurring in men. On average, men with localized prostate cancer have a high 10-year survival rate, and many can be cured. However, men with metastatic castrate-resistant prostate cancer have incurable disease with poor survival despite intensive therapy. This unmet need has led to recent advances in therapy aimed at treating bone metastases resulting from prostate cancer. The bone microenvironment lends itself to metastases in castrate-resistant prostate cancer, as a result of complex interactions between the microenvironment and tumor cells. The development of (223)radium dichloride (Ra-223) to treat symptomatic bone metastases has improved survival in men with metastatic castrate-resistant prostate cancer. Moreover, Ra-223 may have effects on the tumor microenvironment that enhance its activity. Ra-223 treatment has been shown to prolong survival, and its effects on the immune system are under investigation. Because prostate cancer affects a sizable portion of the adult male population, understanding how it metastasizes to bone is an important step in advancing therapy. Clinical trials that are underway should yield new information on whether Ra-223 synergizes effectively with immunotherapy agents and whether Ra-223 has enhancing effects on the immune system in patients with prostate cancer. Springer US 2018-01-29 2018 /pmc/articles/PMC5801387/ /pubmed/29380085 http://dx.doi.org/10.1007/s10555-017-9719-4 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Clinical Logothetis, Christopher Morris, Michael J. Den, Robert Coleman, Robert E. Current perspectives on bone metastases in castrate-resistant prostate cancer |
title | Current perspectives on bone metastases in castrate-resistant prostate cancer |
title_full | Current perspectives on bone metastases in castrate-resistant prostate cancer |
title_fullStr | Current perspectives on bone metastases in castrate-resistant prostate cancer |
title_full_unstemmed | Current perspectives on bone metastases in castrate-resistant prostate cancer |
title_short | Current perspectives on bone metastases in castrate-resistant prostate cancer |
title_sort | current perspectives on bone metastases in castrate-resistant prostate cancer |
topic | Clinical |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801387/ https://www.ncbi.nlm.nih.gov/pubmed/29380085 http://dx.doi.org/10.1007/s10555-017-9719-4 |
work_keys_str_mv | AT logothetischristopher currentperspectivesonbonemetastasesincastrateresistantprostatecancer AT morrismichaelj currentperspectivesonbonemetastasesincastrateresistantprostatecancer AT denrobert currentperspectivesonbonemetastasesincastrateresistantprostatecancer AT colemanroberte currentperspectivesonbonemetastasesincastrateresistantprostatecancer |